Acute promyelocytic leukaemia and acquired α-2-plasmin inhibitor deficiency: A retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients

Hematological Oncology

Volumn 26, Issue 4, 2008, Pages 241-246

  Wassenaar, Tim ^a,b,c   Black, J ^a   Kahl, B ^a,b   Schwartz, B ^a,b,d   Longo, W ^a,b   Mosher, D ^a,b   Williams, E ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c University of Illinois ^*  (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Acute promyelocytic leukaemia; Anti fibrinolytic agents; Fibrinolysis

Indexed keywords

ALPHA 2 ANTIPLASMIN; AMINOCAPROIC ACID; ANTHRACYCLINE; CARBOPLATIN; DAUNORUBICIN; ETOPOSIDE; HEPARIN; RETINOIC ACID; VITAMIN K GROUP; ANTIFIBRINOLYTIC AGENT; ANTIPLASMIN;

ADULT; ALPHA 2 ANTIPLASMIN DEFICIENCY; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INCIDENCE; INFECTION; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN BLOOD LEVEL; RISK FACTOR; RISK REDUCTION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; BLEEDING; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; MIDDLE AGED; RETROSPECTIVE STUDY;

6-AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; ANTIPLASMIN; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 58949088137     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.867     Document Type: Article

References (29)

1. Grimwade D, Howe K, Langabeer S, et al. Establishing the presence of the t(15:17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunoflourescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party. Br J Haematol 1996; 94(3): 557-573.
2. Goldberg M, Ginsberg D, Mayer R, et al. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 1987; 16(1): 187-191.
3. Menell J, Cesarman G, Jacovina A, McLaughlin M, Lev E, Häjjar K. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340(13): 994-1104.
4. Olwill S, McGlynn H, Gilmore W, Alexander H. All-trans retinoic acid-induced down regulation of annexin II expression in myeloid leukaemia cell lines is not confined to acute promyelocytic leukaemia. Br J Haematol 2005; 131: 258-264.
5. Avvisati G, Ten Cate J, Sturk A, Lamping R, Petti M, Mandelli F. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukemia. Br J Haematol 1988; 70(1): 43-48.
6. Masamitsu Y, Matsushita T, Asou N, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol 2007; 78: 213-219.
7. Tallman M, Anderson J, Schiffer C, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337(15): 1021-1028.
8. Sanz M, Vellenga E, Rayon C, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004; 104(12): 3490-3493.
9. Di Bona E, Avvisati G, Castaman G, et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukemia. Br J Haematol 2000; 108: 689-695.
10. Schwartz B, Williams E, Conlan M, Mosher D. Epsilon-amino-caproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency. Ann Intern Med 1986; 105(6): 873-876.
11. Saba H, Morelli G. The pathogenesis and management of disseminated intravascular coagulation. Clin Adv Hematol Oncol 2006; 4(12): 919-926.
12. Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost 2001; 27(6): 593-604.
13. Zhang X, Hu Y, Hong M, et al. Effects of arsenic trioxide or retinoic acid on mRNA and protein expression of tissue factor and thrombomodulin and procoagulant activity in NB4 cells. Chin J Exp Hematol 2007; 15(2): 391-395.
14. Hirsh J, Anand S, Halperin J, Fuster F V. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 2001; 21: 1094-1096.
15. Tallman M, Kwaan H. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79(3): 543-553.
16. Brower M, Harpel P. Proteolytic cleavage and inactivation of alpha-2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 1982; 257: 9849-9854.
17. Yanada M, Matsushita T, Asou N, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol 2007; 78: 213-219.
18. Ventura GJ, Hester JP, Dixon DO, Khorana S, Keating MJ Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia. Hematol Pathol 1989; 3(1): 23-28.
19. Okajima K, Kohno I, Soe G, Okabe H, Takatsuki K, Binder B. Direct evidence for systemic fibrinogenolysis in patients with acquired alpha 2-plasmin inhibitor deficiency. Am J Hematol 1994; 45(1): 16-24.
20. Alkjaersig N, Fletcher A, Sherry S. Epsilon-aminocaproic acid: an inhibitor of plasminogen activation. J Biol Chem 1959; 234: 832-837.
21. Camarasa M, Olle G, Serra-Prat M, et al. Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial. Br J Anaesth 2006; 95(5): 576-582.
22. Kikura M, Levy J, Tanaka K, Ramsay J. A double-blind, placebocontrolled trial of ε-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg 2006; 202(2): 216-222.
23. Gunawan B, Runyon B. The efficacy and safety of ε-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Aliment Pharmacol Ther 2006; 23: 115-120.
24. Goldberg M, Ginsburg D, Mayer R, et al. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 1987; 69(1): 187-191.
25. Humphries JE, Hess CE, Stewart FM. Acute promyelocytic leukemia: impact of hemorrhagic complications on response to induction chemotherapy and survival. South Med J 1990; 83(10): 1157-1161.
26. Brown J, Olujohungbe A, Chang J, et al. All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia. Br J Haemtol 2000; 110: 1010-1012.
27. Tubbs RR, Benjamin SP, Dohn DE. Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report. J Neurosurg 1979; 51: 94-97.
28. Achiron A, Gornish M, Melamed E. Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia. Stroke 1990; 21: 817-818.
29. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111: 3395-3402.